These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11791470)

  • 41. Teasing apart the complex genetics of human autoimmunity: lessons from rheumatoid arthritis.
    Gregersen PK
    Clin Immunol; 2003 Apr; 107(1):1-9. PubMed ID: 12738244
    [No Abstract]   [Full Text] [Related]  

  • 42. Differences in HLA-DR association with rheumatoid arthritis among migrant Indian communities in South Africa.
    Mody GM; Hammond MG
    Br J Rheumatol; 1994 May; 33(5):425-7. PubMed ID: 8173844
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype.
    de Vries N; Rønningen KS; Tilanus MG; Bouwens-Rombouts A; Segal R; Egeland T; Thorsby E; van de Putte LB; Brautbar C
    Tissue Antigens; 1993 Jan; 41(1):26-30. PubMed ID: 8456440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HLA-DR residues accessible under the peptide-binding groove contribute to polymorphic antibody epitopes.
    Fu XT; Drover S; Marshall WH; Karr RW
    Hum Immunol; 1995 Aug; 43(4):243-50. PubMed ID: 7499171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of T cell receptor/HLA-DRB1*04 molecular modeling to predict site-specific interactions for the DR shared epitope associated with rheumatoid arthritis.
    Penzotti JE; Nepom GT; Lybrand TP
    Arthritis Rheum; 1997 Jul; 40(7):1316-26. PubMed ID: 9214433
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [HLA-DR molecular typing: diagnostic and prognostic value in beginning rheumatoid arthritis].
    Guerne PA
    Schweiz Med Wochenschr Suppl; 1996; 80():12S-13S. PubMed ID: 8830400
    [No Abstract]   [Full Text] [Related]  

  • 47. HLA-DR association in rheumatoid arthritis and the shared susceptibility epitope hypothesis.
    Galeazzi M; Sebastiani GD; Cappellacci S; Lulli P; Mazzilli MC; Tosi R; Tanigaki N
    Arthritis Rheum; 1989 May; 32(5):663-4. PubMed ID: 2470380
    [No Abstract]   [Full Text] [Related]  

  • 48. Autoimmunity versus tolerance: analysis using transgenic mice.
    Taneja V; David CS
    Hum Immunol; 2000 Dec; 61(12):1383-9. PubMed ID: 11163096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lymphocyte responses to DR1/4 restricted peptides in rheumatoid arthritis.
    Skinner MA; Watson L; Geursen A; Tan PL
    Ann Rheum Dis; 1994 Mar; 53(3):171-7. PubMed ID: 8154934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased frequency of Gm(1,2;21) phenotype in HLA-DR4 positive seropositive rheumatoid arthritis.
    Zarnowski H; Mierau R; Werdier D; Antons M; Genth E; Hartl PW
    J Rheumatol; 1986 Oct; 13(5):858-63. PubMed ID: 3493344
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of HLA-DRB alleles on the subclass titres of antibodies against citrullinated peptides.
    Engelmann R; Eggert M; Neeck G; Mueller-Hilke B
    Rheumatology (Oxford); 2010 Oct; 49(10):1862-6. PubMed ID: 20584722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HLA-DRB1 gene sequences in HLA-DR4 positive and negative patients with rheumatoid arthritis.
    Becking A; Pluschke G; Krawinkel U; Melchers I; Peter HH; Lang B
    Eur J Immunogenet; 1993 Apr; 20(2):83-9. PubMed ID: 8494871
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Susceptibility epitope on HLA-DR beta chain for rheumatoid arthritis and the effect of the positivity on the clinical features.
    Takeuchi F; Matsuta K; Watanabe Y; Tokunaga K; Juji T; Miyamoto T
    J Immunogenet; 1989 Dec; 16(6):475-83. PubMed ID: 2484314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect.
    Gibert M; Balandraud N; Touinssi M; Mercier P; Roudier J; Reviron D
    Hum Immunol; 2003 Oct; 64(10):930-5. PubMed ID: 14522089
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A distinctive peptide binding motif for HLA-DRB1*0407, an HLA-DR4 subtype not associated with rheumatoid arthritis.
    Davenport MP; Godkin A; Friede T; Stevanović S; Willis AC; Hill AV; Rammensee HG
    Immunogenetics; 1997; 45(3):229-32. PubMed ID: 8995193
    [No Abstract]   [Full Text] [Related]  

  • 56. Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis.
    van der Helm-van Mil AH; Huizinga TW; de Vries RR; Toes RE
    Arthritis Rheum; 2007 Jun; 56(6):1728-35. PubMed ID: 17534941
    [No Abstract]   [Full Text] [Related]  

  • 57. Excitement--and confusion--about HLA and rheumatoid arthritis.
    Harris ED
    Ann Intern Med; 1995 Aug; 123(3):232-3. PubMed ID: 7598307
    [No Abstract]   [Full Text] [Related]  

  • 58. Tolerance to a self-peptide from the third hypervariable region of HLA DRB1*0401 in rheumatoid arthritis patients and normal subjects.
    Salvat S; Auger I; Rochelle L; Begovich A; Geburher L; Sette A; Roudier J
    J Immunol; 1994 Dec; 153(11):5321-9. PubMed ID: 7963584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Unusual DQA-DR haplotypes in rheumatoid vasculitis.
    Hillarby MC; Ollier WE; Davis M; Davidson J; Sanders PA; Grennan DM
    Br J Rheumatol; 1993 Feb; 32(2):93-6. PubMed ID: 8428242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease mechanisms in rheumatoid arthritis: gene dosage effect of HLA-DR haplotypes.
    Weyand CM; Goronzy JJ
    J Lab Clin Med; 1994 Sep; 124(3):335-8. PubMed ID: 8083576
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.